Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Introduction and Current ART (14 minutes)
  • CME
  • CE

Credits Available
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.25 Nursing contact hours
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: May 12, 2020 Expiration: May 11, 2021
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
ViiV Healthcare
Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Roger Bedimo, MD, MS, FACP
Daniel R. Kuritzkes, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Appropriately counsel patients regarding data from clinical trials evaluating the use of ARV agents to prevent HIV infection
  • Incorporate the results of recent clinical studies when utilizing ARV agents for individualized management of HIV infection
  • Provide insightful counsel to patients and colleagues regarding studies of investigational or recently approved ARV agents and strategies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Joseph J. Eron, Jr., MD

Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV.
Princy N. Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief,
Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP, has disclosed that she has received consulting fees from Amgen, Gilead Sciences, GlaxoSmithKline, Merck, and Theratechnologies; has received funds for research support from Gilead Sciences, GlaxoSmithKline, Merck, and Theratechnologies; and has ownership interest in Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, and Pfizer.

Faculty

Roger Bedimo, MD, MS, FACP

Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas

Roger Bedimo, MD, MS, FACP, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV and funds for research support from ViiV.
Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Merck, and ViiV and funds for research support from Gilead Sciences, Merck, and ViiV.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME services from Salix Pharmaceuticals, Saluda Medical, and Shionogi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, physician assistants, pharmacists, and other healthcare professionals who provide care for patients with HIV infection.

Goal

The goal of this activity is to improve learners’ competence in providing optimal care for HIV-infected patients through the appropriate use of contemporary ARV regimens.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Pharmacist Continuing Education

Credit Designation

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-028-H02-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 12, 2020, through May 11, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Introduction and Current ART (14 minutes)
  • CME
  • CE

Learn how experts view new data on the use of more recently approved ART regimens, including efficacy among key patient subgroups and a more detailed examination of patients who experience virologic failure.
Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Roger Bedimo, MD, MS, FACP
Daniel R. Kuritzkes, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.25 Nursing contact hours
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: May 12, 2020 Expiration: May 11, 2021

This program is divided into several short segments which you can step through using the Video Chapters widget.
PreviousNext

Related Content

Download free slides reviewing key barriers to engagement and retention in care for aging persons with HIV or at risk of HIV

Jonathan Appelbaum, MD, FACP, AAHIVS Patrice A. Harris, MD, MA Bisola Ojikutu, MD, MPH Melanie Reese Elena Rios, MD, MSPH, FACP Released: November 23, 2020

Watch this interactive presentation from CCO to hear expert faculty discuss clinical and structural needs to better care for aging persons with HIV

Jonathan Appelbaum, MD, FACP, AAHIVS Patrice A. Harris, MD, MA Bisola Ojikutu, MD, MPH Melanie Reese Elena Rios, MD, MSPH, FACP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: November 23, 2020 Expired: February 18, 2023

CCO commentary from Babafemi Taiwo, MD, on new data on cabotegravir plus rilpivirine presented at IDWeek 2020 Virtual

Babafemi Taiwo, MBBS Released: November 23, 2020

CCO video: Drs. Jason Halperin and Aadia Rana on ending the HIV epidemic by achieving virologic suppression via rapid ART, care equity, and monitoring

Jason Halperin, MD, MPH Aadia I. Rana, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Physician Assistants: maximum of 1.5 hours of AAPA Category I CME credits Pharmacists: 1.5 contact hours (0.15 CEUs) Released: November 17, 2020 Expired: November 16, 2023

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue